Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
5 evidence topics · 5 sources
Complete response at any time in BOND-003 Cohort C
“As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote